This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Six Month Trial of Lamotrigine vs. Sodium Valproate for Treatment of Mixed Mania

This study has been completed.
Information provided by:
Beth Israel Medical Center Identifier:
First received: September 16, 2005
Last updated: November 24, 2010
Last verified: November 2010
We are comparing the efficacy of Lamotrigine to that of Standard of Care Sodium Valproate for the treatment of Mixed Mania. The study hypothesis is that Lamotrigine will be more efficative for treating mixed mania in patients with Bipolar Disorder.

Condition Intervention Phase
Mixed Mania Bipolar Disorder Drug: Lamotrigine Drug: Sodium Valproate Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: A Randomized Open-Label 6 Month Acute and Maintenance Trial of Lamotrigine vs. Standard of Care Sodium Valproate Monotherapy for Treatment of Mixed Mania.

Resource links provided by NLM:

Further study details as provided by Beth Israel Medical Center:

Estimated Enrollment: 36
Study Start Date: July 2003
Study Completion Date: July 2007
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and females, ages 18-65.
  • Ability to sign an informed consent
  • Diagnosis of Bipolar Mood Disorder I, manic episode.
  • Mania Rating Scale (MRS) score of at least 11
  • HDRS score of at least 18
  • Global Assessment Scale (GAS) scores more than 60.

Exclusion Criteria:

  • Alcohol or substance abuse within the last 6 months
  • Current diagnosis of Obsessive-Compulsive Disorder
  • Current diagnosis of Schizophrenia or Schizoaffective Disorder
  • Previous adverse reaction or allergies to lamotrigine or sodium valproate
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00206778

United States, New York
Beth Israel Medical Center
New York, New York, United States, 10003
Sponsors and Collaborators
Beth Israel Medical Center
Principal Investigator: Igor Galynker, MD, PhD Beth Israel Medical Center
  More Information

Responsible Party: Igor Galynker, MD, Beth Israel Medical Center Identifier: NCT00206778     History of Changes
Other Study ID Numbers: 100-03
Study First Received: September 16, 2005
Last Updated: November 24, 2010

Keywords provided by Beth Israel Medical Center:
Mixed mania
Bipolar Disorder

Additional relevant MeSH terms:
Bipolar Disorder
Bipolar and Related Disorders
Mental Disorders
Valproic Acid
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Enzyme Inhibitors
GABA Agents
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs processed this record on August 18, 2017